CTOs on the Move


 
FocusOne is a Omaha, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Moonlighting Solutions

Moonlighting Solutions is a physician-owned and operated company that provides hospitals with short and long-term physician coverage, specializing in night and weekend call coverage. They also offer permanent placement opportunities for their moonlight...

Akeso Care Management

Akeso Care Management is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Optum

Optum is a leading information and technology-enabled health services business dedicated to helping make the health system work better for everyone. Optum comprises three companies â€" OptumHealth, OptumInsight and OptumRx â€" representing more than 35,000 employees worldwide who collaborate to deliver integrated, intelligent solutions that work to modernize the health system and improve overall population health.

Superior HealthPlan

Austin-based Superior HealthPlan (Superior) is a managed care company that employs more than 3,400 people across nine Texas offices. Superior is a wholly-owned subsidiary of Centene Corporation, a diversified, multi-national healthcare enterprise. Superior is licensed by the Texas Department of Insurance and is a Qualified Health Plan issuer in the Texas Health Insurance Marketplace.

Celator Pharmaceuticals

Celator Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is transforming the science of combination therapy and developing products to improve outcomes for patients with cancer. The Company is working to establish a new treatment paradigm in which rationally-designed, fully-integrated combination products replace combination regimens of individual agents. Celator`s proprietary technology platform, CombiPlex®, identifies the most effective synergistic ratio of the component drugs, optimizes the pharmacology of the drug combination prior to human clinical trials, allows simultaneous administration of the components as a single product and maintains the synergistic ratio of the components after administration thereby exposing tumor cells to the right amounts of drug for the right length of time.